PLUS Trial Livestream Follow Up Podcast
Posted February 22nd
PLUS Trial Results Presentation
Prof Simon Finfer (Sydney, Australia)
Balanced Crystalloids Systematic Review Results Presentation
Assoc Prof Naomi Hammond (Sydney, Australia)
Editorial
Prof Deborah Cook (Hamilton, Canada)
Viewer's Questions
Dr Murali Shyamsundar (Belfast, Northern Ireland)
Answers from Prof Simon Finfer & Assoc Prof Naomi Hammond (both Sydney, Australia)
Panel Discussion
Rob Mac Sweeney hosts a panel discussion on the results of the PLUS trial, including Prof John Kellum (Pittsburgh, USA), Prof Gordon Guyatt (Hamilton, Canada), Dr Tomoko Fujii (Tokyo, Japan) & Prof Jeff Drazen (Boston, USA)
The countdown has begun
Selected Global Timings
Ankara | 23:00 to 00:40 |
Abuja | 21:00 to 22:40 |
Dublin | 20:00 to 21:40 |
Rio de Janerio | 17:00 to 18:40 |
Boston | 15:00 to 16:40 |
Mexico City | 14:00 to 15:40 |
San Francisco | 12:00 to 13:40 |
Tokyo (19th) | 05:00 to 06:40 |
Sydney (19th) | 07:00 to 08:40 |
Schedule
00:00 | PLUS Trial Results | Simon Finfer |
00:20 | Systematic Review & Meta Analysis | Naomi Hammond |
00:30 | Editorial | Deborah Cook |
00:45 | Reply to the Editorial | Simon Finfer Naomi Hammond |
00:50 | Viewer's Questions | Murali Shyamsundar |
01:00 | Panel Discussion | Tomoko Fujii Gordon Guyatt Jeff Drazen |
01:40 | End |
Speakers
Simon Finfer
Professorial Fellow, The George Institute for Global Health and Chair of Critical Care Medicine, Imperial College of London
Simon Finfer is a Professorial Fellow in the Critical Care and Trauma Division at The George Institute for Global Health and Chair of Critical Care Medicine, Faculty of Medicine, Imperial College of London. He is also an Adjunct Professor at the University of New South Wales and is a practicing critical care physician with an appointment as a Senior Staff Specialist at Royal North Shore Hospital and Director of Intensive Care at the Sydney Adventist Hospital, the largest not-for-profit hospital in New South Wales.
Simon was a founding member and is a past-Chair of the Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group, immediate past chair of the Council of the International Sepsis Forum, and a member of the Global Sepsis Alliance Executive. In 2012 he was awarded an honorary doctorate (Doctor of Medicine) by The Friedrich-Schiller University in Germany, an honour awarded once every 10 years. He is a Fellow of the Australian Academy of Health and Medical Science & was appointed and Officer (AO) in the Order of Australia in the Queen’s Birthday Honours 2020.
Naomi Hammond
Associate Professor, University of New South Wales, Australia
Associate Professor Naomi Hammond is the Program Lead in the Critical Care Division at The George Institute for Global Health. She also works part-time as an Intensive Care Nurse Researcher at Royal North Shore Hospital, Sydney, Australia. Naomi holds several other appointments including an NHMRC Emerging Leader Fellowship; Convenor of the ANZICS-CTG Point Prevalence Program; Chair of the Australian College of Critical Care Nurses Research Advisory Panel; and Senior Research Fellow with the Australian Sepsis Network.
One of Naomi’s research interests includes undertaking cross-sectional studies to inform future definitive trials and determine translation into critical care practice. Through her PhD Program she led a bi-national, cross-sectional study over 6 years (ICM, 2015), and the international Fluid TRIP Study (PLOS One, 2017) both of which highlighted changes in ICU fluid resuscitation trends providing the impetus for the NHMRC funded Plasma-Lyte 148® versus Saline (PLUS) Study. Naomi also led the Balanced Salt Solution vs Saline Systematic Review and Meta-analysis collaboration which incorporates the PLUS and BaSICS results.
Twitter: @NaomiHammond
Deborah Cook
Distinguished Professor of Medicine, Clinical Epidemiology & Biostatistics, and Academic Chair of Critical Care, McMaster University, Canada
Dr. Cook is a Distinguished Professor at McMaster University in the Departments of Medicine, Clinical Epidemiology and Biostatistics. She holds a Canada Research Chair in Intensive Care Medicine and is Academic Chair of Critical Care Medicine at McMaster. Dr. Cook was a founding member and Chair of the Canadian Critical Care Trials Group. She is an intensive care consultant at St. Joseph’s Hospital in Hamilton. Dr. Cook has published over 700 peer-review articles. Her multi-method multi-disciplinary research interests include life support technology, prevention of ICU-acquired complications, end-of-life care, and research ethics. Her devoted mentorship of students, trainees and faculty has resulted in creation of the Deborah J. Cook Mentorship Award by the Canadian Critical Care Trials Group. Dr. Cook has received numerous national and international honours for her work – most recently the CIHR Gold Leaf Award for Impact. For her enduring scientific contributions to the improvement of global intensive care and foundational leadership in the first national ICU research network in the world, Dr. Cook was appointed an Officer of the Order of Canada.
John Kellum
Chief Medical Officer for Spectral Medical; Distinguished Professor of Critical Care Medicine, Medicine, Bioengineering and Clinical and Translational Science, University of Pittsburgh
Dr. Kellum is the Chief Medical Officer for Spectral Medical, a late-stage medical device company developing diagnostics and therapeutics for sepsis. He is also a Distinguished Professor of Critical Care Medicine, Medicine, Bioengineering and Clinical and Translational Science and holds an Endowed Chair in Critical Care Research from the University of Pittsburgh. He is Director of the Center for Critical Care Nephrology at the University of Pittsburgh. Dr. Kellum received his medical degree from the Medical College of Ohio in 1984. His postgraduate training includes an internship and residency in Internal Medicine at the University of Rochester, NY, and a Fellowship in Critical Care Medicine at the University of Pittsburgh. His research interests span various aspects of Critical Care Medicine, but center in critical care nephrology, sepsis and multi-organ failure, and clinical epidemiology, including consensus development and research methodology. He has authored more than 750 publications and has won several awards for teaching. He lectures widely and has given more than 500 seminars and invited lectures worldwide related to his research. Dr. Kellum is recognized as a world expert in the field of sepsis by Expertscape whose independent PubMed-based algorithms place him in the top 0.1% of scholars writing about Sepsis over the past 10 years.
Twitter: @kellumja
Tomoko Fujii
ICU Director, Jikei University Hospital, Japan; Senior Research Fellow of the Australian and New Zealand Intensive Care Research Centre, Monash University, Australia
Tomoko is a Senior Research Fellow of the Australian and New Zealand Intensive Care Research Centre in the Department of Epidemiology and Preventive Medicine, Monash University, Australia.
She is an intensive care specialist in Japan and is passionate about research to improve the care of patients with critical illnesses. She regularly delivers presentations both nationally and internationally. Research foci include clinical research in sepsis, acute kidney injury, and fluids. She is managing a phase II multicentre randomised controlled trial of vitamin C therapy in patients with septic shock (VITAMINS).
Twitter: @tomoko_ICU
Gordon Guyatt
Distinguished University Professor in the Departments of Health Research Methods, Evidence and Impact and Medicine at McMaster University in Hamilton, Canada
Gordon Henry Guyatt is Distinguished University Professor in the Departments of Health Research Methods, Evidence and Impact (formerly Clinical Epidemiology & Biostatistics) and Medicine at McMaster University in Hamilton, Canada. He is known for his leadership in evidence-based medicine, a term that first appeared in a single-author paper he published in 1991. Subsequently, a 1992 JAMA article that Guyatt led proved instrumental in bringing the concept of evidence-based medicine to the world's attention. In 2007, The BMJ launched an international election for the most important contributions to healthcare. Evidence-based medicine came 7th, ahead of the computer and medical imaging.
As co-founder and co-chair of the GRADE working group he has been intimately involved in the development and evolution of the GRADE approach. Guyatt's concerns with the role of the medical system, social justice, and medical reform remain central issues that he promoted in tandem with his medical work. On October 9, 2015, he was named to the Canadian Medical Hall of Fame.
Twitter: @GuyattGH
Jeff Drazen
Distinguished Parker B Francis Professor of Medicine,
Harvard Medical School, Boston; NEJM Group Editor & Editor-in-Chief NEJM Evidence.
Jeffrey Drazen joined the New England Journal of Medicine as Editor-in-Chief in 2000 and served in this role until 2019. Under his leadership, NEJM published major papers advancing the science of medicine, including the first descriptions of SARS, timely coverage of the Ebola and Zika virus epidemics, and advances in the treatment of cancer, heart disease and lung disease. During his tenure, NEJM was at the forefront of worldwide efforts to register all clinical trials and to share clinical trial data.
Prof Drazen has served as chief of Pulmonary Medicine at the Beth Israel Hospital in Boston, chief of the combined Pulmonary Divisions of the Beth Israel and Brigham and Women’s Hospitals, and as chief of Pulmonary Medicine at Brigham and Women’s Hospital. In September 2019, Dr. Drazen retired from his role as Editor-in-Chief. He now serves as NEJM Group Editor and as Editor-in-Chief of a new journal, NEJM Evidence, a new monthly digital journal from NEJM Group, presenting innovative original research and fresh, bold ideas in clinical trial design and clinical decision-making.
Twitter: @JeffDrazen
Registration for CPD / CME Points
Registration for CPD / CME points has now closed
Related Trials
Intensive Care Unit
- Zampieri. Effect of Intravenous Fluid Treatment With a Balanced Solution vs 0.9% Saline Solution on Mortality in Critically Ill PatientsThe BaSICS Randomized Clinical Trial. JAMA 2021;epublished August 10th
- Semler. Balanced Crystalloids versus Saline in Critically Ill Adults (SMART). N Engl J Med 2018;epublished February 27th
- Young. Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit (SPLIT Trial). JAMA 2015;314(16):1701-1710
Emergency Department
BASICS Trial Result Presentation Livestream
Presented at a Critical Care Reviews Trial Results Livestream, August 10th, 2021